B. Riley analyst Mayank Mamtani reiterates a Buy rating on Viking Therapeutics (VKTX) with a $96 price target after the ...

Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. I will now turn the call ...

Operator: Good morning and welcome to Agenus Inc.’s Fourth Quarter and Year-End 2024 Earnings Conference Call. Currently all ...

[Operator instructions] And our next question comes from the line of Mayank Mamtani with B. Riley Securities. Please go ahead. Good morning, team. Thanks for taking our questions, and appreciate ...

Operator Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. Currently, all ...

Brian Culley; Chief Executive Officer, Director; Lineage Cell Therapeutics Inc Jill Howe; Chief Financial Officer; Lineage Cell Therapeutics Inc Jack Allen; Analyst; Robert W. Baird & Co Inc Thank you ...

In terminal catalyst for 2025 on the regulatory updates, stay tuned. Sure, Mayank. Thank you for that. And if you recall, and I'm sure that you recall, but in general, the first stage of ...

Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. Currently, all participants are in a listen-only mode. A question-and-answer session will ...

Agenus Inc. (AGEN) experienced a notable premarket stock increase of 9.77% following the release of its Q4 2024 earnings report. The company reported a Q4 2024 revenue of $26.8 million and a net ...

Lineage Cell Therapeutics reported its Q4 2024 earnings with a notable increase in revenue compared to the previous year, although the company continued to operate at a loss. The stock showed a ...